Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 47

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 47
---
 the nine months ended September 30, 2025 were relatively consistent with the expenses incurred in the same period of the prior year, reflecting stable operating activities across the business.

Sales and Marketing Expense

Nine months ended September 30,(in millions)20252024Change% ChangeSales and marketing expense$212.1 212.1 $— — %Sales and marketing expense as a % of total revenue34.5 %33.8 %

Sales and marketing expense for the nine months ended September 30, 2025 were relatively consistent with the expenses incurred in the same period of the prior year, reflecting stable operating activities across the business. 

General and Administrative Expense

Nine months ended September 30,(in millions)20252024Change% ChangeGeneral and administrative expense$201.2 211.9 $(10.7)(5)%General and administrative expense as a % of total revenue32.7 %33.8 %

General and administrative expense decreased by $10.7 million for the nine months ended September 30, 2025 compared to the prior year primarily due to a $6.8 million decrease in amortization for previously impaired intangible assets, and a decrease of $3.4 million in consulting fees.  

26

Goodwill and Long-lived Asset Impairment Charges

Nine months ended September 30,(in millions)20252024Change% ChangeGoodwill and long-lived asset impairment charges$316.7 $13.8 $302.9 2195 %Goodwill and long-lived asset impairment charges as a % of total revenue51.5 %2.2 %

Goodwill and long-lived asset impairment charges in the nine months ended September 30, 2025 included goodwill impairment charges of $234.7 million and intangible asset impairment charges of $82.0 million related to our Women's Health and Pharmacogenomics reporting units. In the prior year, we recognized $13.8 million of losses in connection with the sale of the EndoPredict business.

Other Income (Expense), Net

Nine months ended September 30,(in millions)20252024Change% ChangeOther income (expense), net$(4.7)$0.1 $(4.8)(4800)%

Other income (expense), net for the nine months ended September 30, 2025 increased $4.8 million as compared to the same period in the prior year primarily due to an increase in interest expense for the